Verification of drug license & valid prescription is strongly advised for the users before dealing in medicines

Ceftriaxone 1000mg Sulbactam 500mg Injection For Human Use

₹ 195/Vial

Usage / ApplicationHuman Use
Strength1.5 gm
Pack TypeVial
CompositionCeftriaxonen 1000mg + Sulbactam 500mg
BrandLIBCEF-SB
Packaging TypeVial
FormSolution
Brand NameLIBCEF-SB
AvailabilityIn Stock
View in Hindi सेफ़्ट्रियाक्सोन 1000 मिलीग्राम सुल्बैक्टम 500 मिलीग्राम इंजेक्शन मानव उपयोग के लिए
StayHappi Ceftriaxone+Sulbactam 1000mg/500mg Injection contains two different medicines, Ceftriaxone and Sulbactum, that work together to kill the bacteria that cause infections. Ceftriaxone works by stopping the growth of bacteria. Sulbactam reduces resistance and enhances the activity of Ceftriaxone against bacteria.

Find products similar to Ceftriaxone 1000mg Sulbactam 500mg Injection For Human Use

Find related categories

Shipping Information

PriceExcluding all taxes
Ships fromPanchkula
ShippingAs per delivery location

Interested in this product?Get Latest Price from the seller

About the Company

GST Registration Date
03-08-2021
Legal Status of Firm
Limited Company
Nature of Business
Trader - Wholesaler/Distributor
Number of Employees
Upto 10 People
Annual Turnover
40 L - 1.5 Cr
IndiaMART Member Since
Jan 2021
GST
06AAICD3938K1ZD

Established in the year of 2021, We “DR. LBR Medi Care & Research Private Limited” are Wholesaler, Trader and Distributer of Pharmaceutical Tablets, Pharmaceutical Syrup, Pharmaceutical Capsules, Pharmaceutical Injection, Pharmacetical Softgel Capsule, Pharmaceutical Oral Suspension. We direct all our activities to cater the expectations of customers by providing them excellent quality products as per their gratification. Moreover, we follow moral business policies and crystal pure transparency in all our transactions to keep healthy relations with the customers.

For our accomplishment story, we are grateful to our (C.E.O) “Mr. Roshan Lal Jindal whose continual backing and direction have been useful to us for attaining exponential development in the current market.